Last update 21 Jun 2024

HRS-8807

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
HRS 8807, HRS8807
Target
SERCA
Mechanism
SERCA inhibitors(Sarcoplasmic reticulum calcium-transporting ATPase inhibitors)
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal Diseases
Active Indication
Advanced breast cancerER-positive/HER2-negative Breast Cancer
Inactive Indication-
Originator Organization
Shanghai Hengrui Pharmaceutical Co., Ltd.Shanghai Hengrui Pharmaceutical Co., Ltd.
Active Organization
Shanghai Hengrui Pharmaceutical Co., Ltd.Shanghai Hengrui Pharmaceutical Co., Ltd.Jiangsu Hengrui Pharmaceuticals Co., Ltd.Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-

Related

2
Clinical Trials associated with HRS-8807
CTR20211746 / RecruitingPhase 1
HRS8807单药及联合SHR6390在ER阳性、HER2阴性转移性或局部晚期乳腺癌患者中的安全性、耐受性及药代动力学的单臂、开放、多中心I期临床研究
[Translation] A single-arm, open-label, multicenter phase I clinical study on the safety, tolerability and pharmacokinetics of HRS8807 alone and in combination with SHR6390 in patients with ER-positive, HER2-negative metastatic or locally advanced breast cancer
NCT04993430 / RecruitingPhase 1
A Phase 1, Single Arm, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer
100 Clinical Results associated with HRS-8807
Login to view more data
100 Translational Medicine associated with HRS-8807
Login to view more data
100 Patents (Medical) associated with HRS-8807
Login to view more data
100 Deals associated with HRS-8807
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced breast cancerPhase 1
CN
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
26 Oct 2021
ER-positive/HER2-negative Breast CancerPhase 1
CN
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
26 Oct 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT04993430 (ESMO2023)
ManualManual
Phase 1
ER-positive/HER2-negative Breast Cancer
ER positive | HER2 negative
7
rqpbdqthtv(wmuvmccmis) = uzwcnlkipt xpyzdzfwew (pgpqhlfatj )
View more
Positive
23 Oct 2023
(150 mg)
ozmwaenftk(wzldhwbllm) = xdjiyyryrk yxcuyxxatw (nvuywgagdb, 9.4-99.2)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free